3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Laryngeal Diseases
1
Head and Neck Neoplasms
1
Interventions
Cisplatin
75
Cetuximab
63
Radiotherapy
38
pembrolizumab
29
Radiotherapy, Intensity-Modulated
28
Carboplatin
25
Fluorouracil
24
Docetaxel
24
Paclitaxel
19
Erlotinib Hydrochloride
13
Nivolumab
12
Radiation
10
Pemetrexed
10
durvalumab
8
Gemcitabine
8
Drug Therapy
8
Bevacizumab
7
zalutumumab
6
Surgical Procedures, Operative
6
Panitumumab
6
Lapatinib
6
Everolimus
6
Albumin-Bound Paclitaxel
6
130-nm albumin-bound paclitaxel
6
epacadostat
5
Standard of Care
5
Oxaliplatin
5
Gefitinib
5
Afatinib
5
Radiosurgery
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Head and Neck Neoplasms
×
monalizumab
×
Clear all
NCT04590963
2026-06-01
INTERLINK-1
AstraZeneca
Phase 3
Active not recruiting
370 enrolled
21 charts